9-position Substituted Patents (Class 514/180)
-
Patent number: 6765001Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.Type: GrantFiled: December 21, 2001Date of Patent: July 20, 2004Assignee: Medicis Pharmaceutical CorporationInventors: Eugene H. Gans, Mitchell S. Wortzman
-
Patent number: 6762175Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.Type: GrantFiled: April 5, 2002Date of Patent: July 13, 2004Assignee: Norsk Hydro ASAInventors: Finn Myhren, Bernt Børretzen, Are Dalen, Marit Liland Sandvold
-
Patent number: 6759399Abstract: The method of treating narcotic withdrawal symptoms in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound having anti-mineralocorticoid activity sufficient to treat narcotic withdrawal symptoms.Type: GrantFiled: March 27, 2000Date of Patent: July 6, 2004Assignee: Aventis Pharma S.A.Inventors: Francis Petit, Daniel Philibert, Nick Goeders
-
Patent number: 6680310Abstract: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.Type: GrantFiled: July 22, 2002Date of Patent: January 20, 2004Assignee: Corcept Therapeutics, Inc.Inventors: Joseph K. Belanoff, Alan F. Schatzberg
-
Patent number: 6677326Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.Type: GrantFiled: October 1, 2002Date of Patent: January 13, 2004Assignee: Arakis, Ltd.Inventors: Hazel Judith Bardsley, Robin Mark Bannister, Julian Clive Gilbert
-
Patent number: 6663848Abstract: A method for crystallizing a substance, especially an inhalable medicament, comprising the following steps: (a) dissolving said substance in a solvent, to produce a solution of said substance, (b) producing a segmented stream which consists of alternating segments of said solution of the substance and of a transport medium, (c) introducing said segmented stream into the first end of a retention stretch, which retention stretch has a first end and a second end, so that said segmented stream passes from said first end to said second end of said retention stretch, and exits from the second end of the retention stretch, (d) cooling the retention stretch, to thereby bring about crystallization of the substance in the segments of solution, in the segmented stream, as said segmented stream passes through the retention stretch, and (e) separating the crystals of material from the segmented stream as it exits from the second end of the retention stretch.Type: GrantFiled: April 18, 2002Date of Patent: December 16, 2003Assignee: Boehringer Ingelheim Pharma KGInventors: Joerg Schiewe, Bernd Zierenberg
-
Patent number: 6656970Abstract: The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.Type: GrantFiled: March 8, 2001Date of Patent: December 2, 2003Assignee: Dabur Research FoundationInventors: Anand C. Burman, Rama Mukherjee, Honey Bala, Dhiraj Khattar
-
Patent number: 6641800Abstract: Pressurized aerosol composition for administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer soluble in the liquefied hydrofluoroalkane which is selected from polymers including recurring amide containing structural units, copolymers of amide containing units and carboxylic acid ester units, polyvinylacetate and acrylic acid/methacrylic acid ester copolymers.Type: GrantFiled: July 13, 2000Date of Patent: November 4, 2003Assignee: Fisons Ltd.Inventors: Suresh N Mistry, Mark Gibson
-
Patent number: 6579862Abstract: The invention provides a method of using pregnadienones and pregnadienols represented by the structural formula (I): containing at least one olefinic bond in or on their D-ring for the treatment of hyperlipidemic and hyperglycemic conditions in mammals wherein X═OH or O and the olefinic bonds are at 4(5); 5(6); 16(17); or 17(20) or various combinations, and wherein the compounds contain at lest one olefinic bond in or on their D-ring. The method comprises administering an effective amount of said compounds to recipient mammals.Type: GrantFiled: March 30, 1999Date of Patent: June 17, 2003Assignee: Council of Scientific & Industrial ResearchInventors: Ram Pratap, Ram Chandra Gupta, Ramesh Chander, Ashok Kumar Khanna, Arvind Kumar Srivastava, Deepak Raina, Satyavan Singh, Savita Srivastava, Anil Kumar Rastogi, Omkar Prasad Asthana, Swarn Nityanand, Nitya Anand, Ashim Ghatak, Narinder Kumar Kapoor, Sukh Dev
-
Patent number: 6579863Abstract: Disclosed are (i) compounds of a steroid, a &bgr;-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, &bgr;-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO−), or as the neutral species, nitric oxide (NO•) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.Type: GrantFiled: October 13, 2000Date of Patent: June 17, 2003Assignee: Nitromed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Stewart K. Richardson
-
Publication number: 20030032631Abstract: A method for the improved treatment of blood-borne cancers, such as lymphomas, leukemia, and myeloma. The method comprises the oral administration of an effective amount of a topically active corticosteroid to a patient who has undergone hematopoietic cell transplantation. Administration of the TAC controls a graft-versus-leukemia (GVL) reaction that is induced following a hematopoietic cell transplantation, so that a GVHD reaction does not develop, or is reduced in severity. The GVL reaction effects killing of cancerous tumor cells in the blood, mediated by the cells derived from the hematopoietic cell transplantation.Type: ApplicationFiled: August 13, 2001Publication date: February 13, 2003Inventors: George B. McDonald, Nicholas Stergiopoulos
-
Patent number: 6488960Abstract: The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.Type: GrantFiled: September 13, 2001Date of Patent: December 3, 2002Assignee: Arakis Ltd.Inventor: Hazel Judith Bardsley
-
Publication number: 20020165211Abstract: There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) 1Type: ApplicationFiled: February 4, 2002Publication date: November 7, 2002Inventors: Keith Biggadike, Amyn Pyarali Sayani, Ian Richard Buxton, Kenton Lewis Reed
-
Patent number: 6451287Abstract: Amphiphilic fluorinated block copolymers are disclosed which are useful for increasing the dispersability of particles, preferably drug particles, in a fluorine-containing propellant.Type: GrantFiled: May 26, 2000Date of Patent: September 17, 2002Assignee: Smithkline Beecham CorporationInventors: Joseph M. Desimone, Terri Johnson Carson, John F. Miller, Sharon Wells
-
Patent number: 6444660Abstract: The present invention is directed to novel lipid soluble steroid prodrugs, compositions comprising steroid prodrugs, and uses of the same.Type: GrantFiled: February 3, 2000Date of Patent: September 3, 2002Assignee: Imarx Therapeutics, Inc.Inventors: Evan C. Unger, DeKang Shen
-
Patent number: 6436368Abstract: Described is a process for preparing beclomethsaone dipropionate Freon® clathrate comprising the use of an agent which selectively binds methanol to selectively remove methanol from a mixture of methanol and Freon® 11 containing beclomethasone dipropionate.Type: GrantFiled: October 17, 2000Date of Patent: August 20, 2002Assignee: Schering CorporationInventors: George M. Love, Stanley Rosenhouse
-
Patent number: 6426339Abstract: The use of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent, is disclosed.Type: GrantFiled: April 3, 2000Date of Patent: July 30, 2002Assignee: Children's Medical Center CorporationInventors: Charles B. Berde, Robert S. Langer, Joanne Curley, Jenny Castillo
-
Patent number: 6395746Abstract: Methods of treating or preventing ophthalmic, otic, and nasal infections and attendant inflammation are described. The methods utilize ophthalmic, otic, and nasal compositions containing a new class of antibiotics (e.g. trovafloxacin). The compositions also contain one or more anti-inflammatory agents (e.g. dexamethasone). The compositions are utilized to treat ophthalmic, otic, and nasal conditions by topically applying the compositions to the affected tissues.Type: GrantFiled: September 22, 2000Date of Patent: May 28, 2002Assignee: Alcon Manufacturing, Ltd.Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
-
Patent number: 6369115Abstract: A dry powder formulation for treatment of pulmonary conditions, via inhalation, includes an effective amount of formoterol or a salt or solvate thereof, in a dry powder form, an effective amount of fluticasone, in a dry powder form, and an excipient. A method for preparing a physically stable dry powder formulation for inhalation includes the steps of micronizing a first active polar drug, a second active non-polar drug, and a polar excipient. The second non-polar active drug is first blended with the excipient to form an intermediate mixture. The intermediate mixture is then blended with the first active polar drug. The increased separation of the polar drug and polar excipient stabilizes the formulation.Type: GrantFiled: March 20, 2000Date of Patent: April 9, 2002Assignee: Dura Pharmaceuticals, Inc.Inventor: Gary Ward
-
Patent number: 6350739Abstract: The present invention in various embodiments provides methods of treating stroke and conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the delivery of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing hormones that are non-sex hormones is also provided. A method of treating stroke with ent-17&bgr;-estradiol, and a method of synthesis, and compounds produced from the synthesis are provided.Type: GrantFiled: August 11, 1999Date of Patent: February 26, 2002Assignees: University of Florida Resarch Foundation, Inc., Washington UniversityInventors: James W. Simpkins, Douglas F. Covey
-
Patent number: 6344448Abstract: A method and compound having betamethasone dipropionate and all-trans-retinoic is disclosed for the treatment of hair loss. The method also includes identifying any underlying conditions causing hair loss and administration of a salve of betamethasone dipropionate and all-trans-retinoic acid to the affected areas.Type: GrantFiled: July 11, 1994Date of Patent: February 5, 2002Assignee: STB Family Limited PartnershipInventor: Sandra Brown
-
Patent number: 6339078Abstract: The present invention provides methods of conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the delivery of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing non-sex hormones is also provided.Type: GrantFiled: July 20, 1999Date of Patent: January 15, 2002Assignee: University of Florida Research Foundation, Inc.Inventors: James W. Simpkins, Katherine D. Gordon, Robert J. Leonard
-
Patent number: 6326365Abstract: The present invention provides methods of conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the intravenous administration of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing non-sex hormones is also provided.Type: GrantFiled: July 20, 1999Date of Patent: December 4, 2001Assignees: Apollo BioPharmaceutics, Inc., University of Florida Research Foundation, Inc.Inventors: James W. Simpkins, Katherine D. Gordon, Robert J. Leonard
-
Patent number: 6319914Abstract: The invention comprises methods for conferring a cytoprotective effect on a population of cells, such as providing a polycyclic phenolic compound in a physiologically acceptable formulation, and administering the formulation in an effective dose to the population of cells.Type: GrantFiled: July 12, 1999Date of Patent: November 20, 2001Assignees: Apollo BioPharmaceuticals, Inc., University of Florida Research Foundation, Inc.Inventors: James W. Simpkins, Katherine D. Gordon, Pattie S. Green
-
Patent number: 6319901Abstract: Methods for improving the efficiency of electroporation protocols as well as methods to enhance the permeabilized state, in order to improve the intracellular delivery of therapeutic substances, involve the use of at least one agent which is capable of prolonging the permeability of the cell membranes in the tissue exposed to an electroporation-inducing electrical field.Type: GrantFiled: October 15, 1998Date of Patent: November 20, 2001Assignee: Ichor Medical Systems, Inc.Inventors: Robert M. Bernard, Andrew W. Hannaman, Silvia Sfiligoi
-
Publication number: 20010007867Abstract: This invention relates to compounds of the formula 1Type: ApplicationFiled: December 13, 1999Publication date: July 12, 2001Inventor: YUHPYNG L. CHEN
-
Patent number: 6241969Abstract: The present invention provides compositions containing corticosteroid compounds as active agents for the treatment of ailments and diseases of the respiratory tract, particularly the lungs, by way of nasal and pulmonary administration. The corticosteroid compounds are present in a dissolved state in the compositions. The compositions can be formulated in a concentrated, essentially non-aqueous form for storage or in a diluted, aqueous-based form for ready delivery. In a preferred embodiment, the corticosteroid composition contains an ethoxylated derivative of vitamin E and/or a polyethylene glycol fatty acid ester as the high-HLB surfactant present in the formulation. The compositions are ideally suited for inhaled delivery with a nebulizer or for nasal delivery.Type: GrantFiled: June 26, 1998Date of Patent: June 5, 2001Assignee: Elan Corporation plcInventors: Zahir Saidi, Boris Klyashchitsky
-
Patent number: 6228850Abstract: Use of betulinic acid and/or its derivatives for inhibiting and/or preventing angiogenesis is described. Compositions containing betulinic acid derivatives with or without betulinic acid can be used for these purposed.Type: GrantFiled: October 6, 1998Date of Patent: May 8, 2001Assignee: Dabur Research FoundationInventors: Manu Jaggi, Sunder Ramadoss, Praveen Rajendran, Mohammad Jamshed Ahmad Siddiqui
-
Patent number: 6225297Abstract: This invention relates to a combination product that consists of individual dosage units of a competitive progesterone antagonist and, in addition, sequentially provided individual dosage units of a compound with gestagenic action, as well as its use for the production of contraceptives based on the inhibition of implantation (receptivity inhibition).Type: GrantFiled: November 1, 1996Date of Patent: May 1, 2001Assignee: Schering AkitiengesellschaftInventors: Klaus Stockemann, Kristof Chwalisz
-
Patent number: 6218435Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA.Type: GrantFiled: July 17, 1998Date of Patent: April 17, 2001Inventors: James Henry, Gurpreet Ahluwalia, Douglas Shander
-
Patent number: 6204245Abstract: The invention provides compositions and methods for treatment of narcolepsy or isolated cataplexy. Such methods entail administering a therapeutically effective regime of at least one immunosuppressive agent. The methods are particularly useful for prophylactic and therapeutic treatment of narcolepsy or isolated cataplexy.Type: GrantFiled: September 17, 1999Date of Patent: March 20, 2001Assignee: The Regents of the University of CaliforniaInventors: Jerome M. Siegel, Lisa N. Boehmer
-
Patent number: 6172054Abstract: Angiostatic agents and another IOP lowering compound are combined in ophthalmic compositions to treat glaucoma and ocular hypertension. Methods for treating glaucoma and ocular hypertension are also disclosed.Type: GrantFiled: June 15, 1995Date of Patent: January 9, 2001Assignee: Alcon Laboratories, Inc.Inventor: Abbot F. Clark
-
Patent number: 6172055Abstract: Apoptotic cell death in a fully differentiated, non-dividing cell such as a neuron is caused by an abortive attempt of the cell to re-enter or pass through the mitotic cycle. Therefore, agents which prevent such entry or passage are effective in preventing, or at least delaying, apoptotic cell death and are therefore useful in the treatment of neurodegenerative diseases in general, including stroke, Alzheimer's disease, Parkinson's disease and motor-neuron disease in particular.Type: GrantFiled: August 14, 1998Date of Patent: January 9, 2001Assignee: Eisai Co., Ltd.Inventors: Lee Laurence Rubin, Susan Frances Brooks
-
Patent number: 6143736Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.Type: GrantFiled: July 8, 1999Date of Patent: November 7, 2000Assignee: CoCensys, Inc.Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp
-
Patent number: 6096731Abstract: A method for preventing tissue damage associated with graft-versus-host disease in a patient having undergone hematopoietic cell transplantation, and host-versus-graft disease in a patient having undergone organ allograft transplantation. The method includes orally administering to the patient a prophylactically effective amount of a topically active corticosteroid, such as beclomethasone dipropionate, for a period of time following hematopoietic cell or organ allograft transplantation, and prior to the presentation of symptoms associated with graft-versus-host disease or host-versus-graft disease. Representative tissues includes tissue of the intestine and liver, while representative tissue damage includes inflammation thereof.Type: GrantFiled: September 10, 1998Date of Patent: August 1, 2000Assignee: Institute for Drug Research, Inc.Inventor: George B. McDonald
-
Patent number: 6093389Abstract: The present invention provides a composition for attracting termites containing a steroid derivative of formula I ##STR1## The present invention also provides a method for attracting or controlling termites with the composition.Type: GrantFiled: December 1, 1997Date of Patent: July 25, 2000Assignee: American Cyanamid CompanyInventors: Deborah L. Galinis, Sven P. Strnad
-
Patent number: 6090800Abstract: The present invention is directed to novel lipid soluble steroid prodrugs compositions comprising steroid prodrugs, and uses of the same.Type: GrantFiled: May 6, 1997Date of Patent: July 18, 2000Assignee: Imarx Pharmaceutical Corp.Inventors: Evan C. Unger, DeKang Shen
-
Patent number: 6046187Abstract: The use of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent, is disclosed.Type: GrantFiled: September 16, 1996Date of Patent: April 4, 2000Assignee: Children's Medical Center CorporationInventors: Charles B. Berde, Robert S. Langer, Joanne Curley, Jenny Castillo
-
Patent number: 6028106Abstract: The invention provides a method for the treatment and prevention of urinary incontinence in mammals, e.g., human males and females, especially nonpregnant female mammals, by administering a nitric oxide synthase substrate and/or nitric oxide donor, alone or in combination with an estrogenic agent and/or a progestational substance, with or without supplementation with an alpha-adrenergic agonist, beta-adrenergic receptor blocking agent, cholinergic-receptor blocking compound or a cholinergic-receptor-stimulating drug, as well as pharmaceutical compositions useful in practicing the methods of this invention.Type: GrantFiled: October 29, 1997Date of Patent: February 22, 2000Assignees: Schering Aktiengesellschaft, Board of Regents, The Univ. of TX SystemInventors: Robert E. Garfield, Kristof Chwalisz
-
Patent number: 6028066Abstract: The present invention describes, inter alia, novel prodrugs comprising fluorinated amphiphiles, compositions comprising the novel prodrugs, and methods of use of the prodrugs and compositions.Type: GrantFiled: July 2, 1997Date of Patent: February 22, 2000Assignee: Imarx Pharmaceutical Corp.Inventor: Evan C. Unger
-
Patent number: 5998395Abstract: Inflammatory dermatoses are controlled and cleared by topical application to the affected areas of the skin of a composition containing both a corticosteroid and a retinoid. The combined therapy is more effective than either active ingredient alone and is particularly effective for chronic dermatoses which are or have become resistant to corticosteroid treatment alone. After clearing has been obtained with once or twice daily applications of the corticosteroid-retinoid composition, usually after several weeks, clearance can be maintained by less frequent application or lower concentrations of the composition or by application of only one of the corticosteroid or retinoid, less potent corticosteroids, or other non-steroidal therapies, depending upon the particular dermatosis being treated.Type: GrantFiled: September 10, 1993Date of Patent: December 7, 1999Inventor: Albert M. Kligman
-
Patent number: 5990099Abstract: Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.Type: GrantFiled: December 19, 1997Date of Patent: November 23, 1999Assignee: Alcon Laboratories, Inc.Inventor: Abbot F. Clark
-
Patent number: 5972920Abstract: One or more formulations for treating psoriasis and other skin disorders characterized by redness, itching, flaking, scaling, and plaque-type growth. The formulation includes a carrier component, one or more active ingredient components, and a surfactant component. The carrier preferably includes an alcohol in substantially equal volume with isopropyl myristate. The active ingredient component preferably includes a superpotent or high-potency corticosteroid such as clobetasol propionate, an anti-flaking ingredient such as zinc pyrithione, or a combination of the two. It may also include an anti-fungal compound. The surfactant component preferably includes an alkyl sulfate such as sodium lauryl sulfate. The formulations made by applied topically either in spray form or as a direct-contact liquid.Type: GrantFiled: February 12, 1998Date of Patent: October 26, 1999Assignee: Dermalogix Partners, Inc.Inventor: William E. Seidel
-
Patent number: 5955439Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation and in particular to a pharmaceutical aerosol formulation which comprises (a) particulate medicament; (b) at least one sugar; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 24, 1997Date of Patent: September 21, 1999Assignee: Glaxo Group LimitedInventor: Alexander Peter Green
-
Patent number: 5895783Abstract: Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -memetic activities, and a TXA.sub.2 antagonist.Type: GrantFiled: July 16, 1993Date of Patent: April 20, 1999Assignees: Schering Aktiengesellschaft, The University of TexasInventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampal Li
-
Patent number: 5885978Abstract: The present invention provides an external therapeutic composition for dermatitis comprising an aqueous solution including a therapeutically effective amount of an adrenal cortical steroid, a cyclodextrin, polysaccharides, and a carrier such as water, prepared by clathrating the adrenal cortical steroid in the cyclodextrin using a homomixer to form a clathrate, and adding the clathrate to an aqueous solution of polysaccharides, while being stirred uniformly, to dissolve the clathrate in the aqueous solution, as well as a method for the treatment of dermatitis in a mammalian subject, which comprises administering to said subject a therapeupically effective amount of the external therapeutic composition for dermatitis described above. The external therapeutic composition for dermatitis according to the present invention is extremely safe and can cure dermatitis such as an atopic dermatitis or the like without side effects.Type: GrantFiled: April 3, 1996Date of Patent: March 23, 1999Assignee: CAC CorporationInventors: Hajime Yamada, Akira Yamada
-
Patent number: 5877169Abstract: The present invention is directed to a method of conferring protection on a population of cells associated with an ischemic focus, in subject, comprising:(a) providing an estrogen compound having insubstantial sex-related activity; and(b) administering an effective cumulative amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Also directed is a method of treating a myocardial infarct in a subject and an ischemic event with the above combination.Type: GrantFiled: November 15, 1996Date of Patent: March 2, 1999Assignee: University of Florida Research Foundation, Inc.Inventor: James W. Simpkins
-
Patent number: 5849265Abstract: A pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon of hydrogen-containing chlorofluorocarbon propellant and a surfactant of general formula (I), wherein n is an integer of 1 to 18; m is an integer of 0 to 17; and R.sup.1, R.sup.2 and R.sup.3 are each independently a hydrogen atom or a C.sub.1-4 alkyl group.Type: GrantFiled: March 27, 1997Date of Patent: December 15, 1998Assignee: Glaxo Wellcome Inc.Inventors: Li Li-Bovet, Keith A. Johnson
-
Patent number: 5840719Abstract: Apoptotic cell death in a fully differentiated, non-dividing cell such as a neuron is caused by an abortive attempt of the cell to re-enter or pass through the mitotic cycle. Therefore, agents which prevent such entry or passage are effective in preventing, or at least delaying, apoptotic cell death and are therefore useful in the treatment of neurodegenerative diseases in general, including stroke, Alzheimer's disease, Parkinson's disease and motor-neuron disease in particular.Type: GrantFiled: May 8, 1996Date of Patent: November 24, 1998Assignee: Eisai Company, Ltd.Inventors: Lee Laurence Rubin, Susan Frances Brooks, deceased
-
Patent number: 5837698Abstract: The present invention relates to a pharmaceutical composition or preparation which comprises hydroxyl containing steroidal hormones and organic nitrite/nitrate or other nitric oxide donating agents.Type: GrantFiled: May 2, 1996Date of Patent: November 17, 1998Assignee: G. D. Searle & Co.Inventors: Foe S. Tjoeng, Mark G. Currie, Mark E. Zupec